Correction to: Nature Biotechnology https://doi.org/101038/ s41587-021-01053 -9, released online 9 September 2021.
In the variation of this News short article at first released, the post ought to have mentioned that in addition to Qiagen’s Therascreen, the FDA likewise authorized Guardant360 CDx from Guardant Health, as buddy diagnostics for Lumakras. In the 4th paragraph, in the 3rd sentence starting “It is authorized for usage with a buddy diagnostic,” completion of the sentence has actually been changed to consist of “or Guardant360 CDx from Guardant Health.”
The online variation of the short article has actually been upgraded.
